Trial · NCT00835991
Glyburide/Metformin 5 mg/500 mg Film-Coated Tablets, Fed
NCT00835991, Phase 1, Completed, Teva Pharmaceuticals USA; results first posted 2009-08-04
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Glyburide/Metformin 5 mg/500 mg Film-Coated Tablets, Fed. Trials, record NCT00835991. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00835991
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Glyburide/Metformin 5 mg/500 mg Film-Coated Tablets, Fed
- NCT number
- NCT00835991
- Status
- Completed
- Phases
- Phase 1
- Enrollment
- 60 participants, actual
- Lead sponsor
- Teva Pharmaceuticals USA
- Conditions
- Healthy
- Interventions
- Glyburide/Metformin 5 mg/500 mg Tablets, Glucovance® 5 mg/500 mg Tablets
- First posted
- 2009-02-04
- Last updated
- 2024-08-19
- Results first posted
- 2009-08-04
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Cmax (Maximum Observed Concentration) - Glyburide | Blood samples collected over 36 hour period | Bioequivalence based on Cmax |
| Primary | AUC0-inf [Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated)] - Glyburide | Blood samples collected over 36 hour period | Bioequivalence based on AUC0-inf |
| Primary | AUC0-t [Area Under the Concentration-time Curve From Time Zero to Time of Last Non-zero Concentration (Per Participant)] - Glyburide | Blood samples collected over 36 hour period | Bioequivalence based on AUC0-t |
| Primary | Cmax (Maximum Observed Concentration) - Metformin | Blood samples collected over 36 hour period | Bioequivalence based on Cmax |
| Primary | AUC0-inf [Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated)] - Metformin | Blood samples collected over 36 hour period | Bioequivalence based on AUC0-inf |
| Primary | AUC0-t [Area Under the Concentration-time Curve From Time Zero to Time of Last Non-zero Concentration (Per Participant)] - Metformin | Blood samples collected over 36 hour period | Bioequivalence based on AUC0-t |
Source ClinicalTrials.gov
Outcomes6
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Cmax (Maximum Observed Concentration) - Glyburide | Blood samples collected over 36 hour period | Data from all subjects who completed the study were included in the statistical analysis. | ng/mL | MEAN |
| PRIMARY | AUC0-inf [Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated)] - Glyburide | Blood samples collected over 36 hour period | Data from all subjects who completed the study were included in the statistical analysis. | ng*h/mL | MEAN |
| PRIMARY | AUC0-t [Area Under the Concentration-time Curve From Time Zero to Time of Last Non-zero Concentration (Per Participant)] - Glyburide | Blood samples collected over 36 hour period | Data from all subjects who completed the study were included in the statistical analysis. | ng*h/mL | MEAN |
| PRIMARY | Cmax (Maximum Observed Concentration) - Metformin | Blood samples collected over 36 hour period | Data from all subjects who completed the study were included in the statistical analysis. | ng/mL | MEAN |
| PRIMARY | AUC0-inf [Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated)] - Metformin | Blood samples collected over 36 hour period | Data from all subjects who completed the study were included in the statistical analysis. | ng*h/mL | MEAN |
| PRIMARY | AUC0-t [Area Under the Concentration-time Curve From Time Zero to Time of Last Non-zero Concentration (Per Participant)] - Metformin | Blood samples collected over 36 hour period | Data from all subjects who completed the study were included in the statistical analysis. | ng*h/mL | MEAN |
Source ClinicalTrials.gov
Results by group12
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Cmax (Maximum Observed Concentration) - Glyburide | Glyburide Metformin | 190.17 | Standard Deviation 68.08 | ng/mL | |
| Cmax (Maximum Observed Concentration) - Glyburide | Glucovance® | 166.48 | Standard Deviation 59.87 | ng/mL | |
| AUC0-inf [Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated)] - Glyburide | Glyburide Metformin | 970.22 | Standard Deviation 328.93 | ng*h/mL | |
| AUC0-inf [Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated)] - Glyburide | Glucovance® | 977.28 | Standard Deviation 402.74 | ng*h/mL | |
| AUC0-t [Area Under the Concentration-time Curve From Time Zero to Time of Last Non-zero Concentration (Per Participant)] - Glyburide | Glyburide Metformin | 942.94 | Standard Deviation 316.17 | ng*h/mL | |
| AUC0-t [Area Under the Concentration-time Curve From Time Zero to Time of Last Non-zero Concentration (Per Participant)] - Glyburide | Glucovance® | 943.45 | Standard Deviation 388.26 | ng*h/mL | |
| Cmax (Maximum Observed Concentration) - Metformin | Glyburide Metformin | 755.10 | Standard Deviation 195.97 | ng/mL | |
| Cmax (Maximum Observed Concentration) - Metformin | Glucovance® | 766.30 | Standard Deviation 210.22 | ng/mL | |
| AUC0-inf [Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated)] - Metformin | Glyburide Metformin | 6308.12 | Standard Deviation 1662.69 | ng*h/mL | |
| AUC0-inf [Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated)] - Metformin | Glucovance® | 6552.79 | Standard Deviation 1833.42 | ng*h/mL |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 results by groupParticipant flow18
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| First Intervention | STARTED | Glyburide Metformin (Test) First | 30 | |
| First Intervention | STARTED | Glucovance® (Reference) First | 30 | |
| First Intervention | COMPLETED | Glyburide Metformin (Test) First | 30 | |
| First Intervention | COMPLETED | Glucovance® (Reference) First | 29 | |
| First Intervention | NOT COMPLETED | Glyburide Metformin (Test) First | 0 | |
| First Intervention | NOT COMPLETED | Glucovance® (Reference) First | 1 | |
| Washout | STARTED | Glyburide Metformin (Test) First | 30 | |
| Washout | STARTED | Glucovance® (Reference) First | 29 | |
| Washout | COMPLETED | Glyburide Metformin (Test) First | 27 | |
| Washout | COMPLETED | Glucovance® (Reference) First | 26 |
1 to 10 of 18Source ClinicalTrials.gov
See all 18 participant flowAdverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00835991
GET https://conductscience.org/api/trials/v1/NCT00835991/registered